Dr Mario F Juruena

Prof. Mario Juruena is a Professor of Affective Disorder and Translational Psychiatry at the Institute of Psychiatry, Psychology and Neuroscience, Centre for Affective Disorders, within the Department of Psychological Medicine at King’s College London, UK (KCL profile). He is also a Consultant Psychiatrist at South London and Maudsley NHS Foundation Trust and the National Affective Disorder Service, where he serves as the Head of the Maudsley Advanced Treatment Service for Difficult-to-Treat Depression and Bipolar Disorders, Suicidal Behaviours (SLaM profile), and Clinical Lead for Maudsley ECT Service (PMOA), the only one at SLaM. Since the very beginning, he also serves as a Consultant Psychiatrist at Maudsley Private Care at SLaM.

Prof. Juruena obtained his medical degree from the Pontifical Catholic University in Brazil, completed his Psychiatry Training at Saint Peter Hospital – Public Health School, and earned an MPhil in Psychopharmacology from the Federal University of São Paulo. He later pursued an MSc in Affective Neuroscience at Maastricht University in the Netherlands and a Diploma in Cognitive Behavioural Therapy (Dip CBT) at the Beck Institute in the USA. He completed his PhD at King’s College London/University of London, focusing on Treatment-Resistant Depression, prediction of treatment response, and stress hormones.

Mario Juruena has authored over 250 original research articles and edited five books. His work primarily explores the neurobiology, diagnosis, pathophysiology, and treatment of Affective Disorders (Clinical Research). He is an editor for the Special Issues of the Journal of Affective Disorders and an Associate Editor for the British Journal of Psychiatry (Open).

He is also an Adjunct Professor at McGovern Medical School, University of Texas, an Honorary Professor at the Federal University of São Paulo, and a Visiting Professor at The Albert Einstein Education, Research Centre and Faculty of Health Sciences.

Juruena’s contributions to psychiatry have been recognised with numerous prestigious awards, including the Senior Clinical Psychopharmacology Award from the British Association for Psychopharmacology, the Robert W. Kerwin Prize from the Royal College of Psychiatrists for the best article in the British Journal of Psychiatry, and the Newton Research Fellowship from the Royal Society and the Academy of Medical Sciences.